The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.
The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19.
复制标题
I型干扰素在COVID-19的发病机理和治疗中的作用。
DOI：
10.3389/fimmu.2020.595739
复制
发表时间：
2020
影响因子：
7.3
通讯作者：
Schreiber G
中科院分区：
文献类型：
--
作者：
Schreiber G
I型干扰素（IFN-1）是60多年前由Isaacs和Lindenman在一项经典实验中首次发现的，他们表明IFN-1具有抗病毒活性。后来，它成为第一批批准的使用异源蛋白表达系统的蛋白质药物之一，这使得它能够大规模生产。它已被批准，并广泛用于多种疾病，包括多发性硬化症，B和C型肝炎以及某些形式的癌症。初步临床数据支持其对埃博拉和SARS等潜在大流行病原体的有效性。尽管如此，更有效和更具体的药物已经在治疗这些疾病中占据了一席之地。COVID-19全球大流行再次提升了IFN-1的地位，成为更有前途的候选药物之一，初步临床试验显示在降低疾病严重程度和持续时间方面有希望的结果。尽管SARS-CoV-2抑制IFNβ的产生，从而阻碍对该病毒的先天免疫应答，但其对外部施用的IFN-1的抗病毒活性敏感。在这篇综述中，我讨论了不同的模式的生物作用的干扰素-是和这些是如何相关的生物物理参数的干扰素-I受体的相互作用和细胞类型的特异性，在光的各种各样的结合亲和力的不同的干扰素-I亚型对共同的干扰素受体。此外，我还讨论了这些可能如何指导IFN-1在抗击COVID-19中的优化使用。
Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its effectiveness against potential pandemic pathogens such as Ebola and SARS. Still, more efficient and specific drugs have taken its place in treating such diseases. The COVID-19 global pandemic has again lifted the status of IFN-Is to become one of the more promising drug candidates, with initial clinical trials showing promising results in reducing the severity and duration of the disease. Although SARS-CoV-2 inhibits the production of IFNβ and thus obstructs the innate immune response to this virus, it is sensitive to the antiviral activity of externally administrated IFN-Is. In this review I discuss the diverse modes of biological actions of IFN-Is and how these are related to biophysical parameters of IFN-I–receptor interaction and cell-type specificity in light of the large variety of binding affinities of the different IFN-I subtypes towards the common interferon receptor. Furthermore, I discuss how these may guide the optimized use IFN-Is in combatting COVID-19.
登录
查看更多内容
影响因子：
11.1
作者：
Bhattacharya, Sabyasachi;Katlinski, Kanstantsin V.;Reichert, Maximilian;Takano, Shigetsugu;Brice, Angela;Zhao, Bin;Yu, Qiujing;Zheng, Hui;Carbone, Christopher J.;Katlinskaya, Yuliya V.;Leu, N. Adrian;McCorkell, Kelly A.;Srinivasan, Satish;Girondo, Melanie;Rui, Hallgeir;May, Michael J.;Avadhani, Narayan G.;Rustgi, Anil K.;Fuchs, Serge Y.
通讯作者：
Fuchs, Serge Y.
影响因子：
4.1
作者：
Francois-Newton, Veronique;Livingstone, Mark;Pellegrini, Sandra
通讯作者：
Pellegrini, Sandra
影响因子：
2.3
作者：
Choubey, Divaker;Moudgil, Kamal D.
通讯作者：
Moudgil, Kamal D.
影响因子：
9
作者：
Channappanavar R;Perlman S
通讯作者：
Perlman S
影响因子：
5.6
作者：
Daczkowski CM;Dzimianski JV;Clasman JR;Goodwin O;Mesecar AD;Pegan SD
通讯作者：
Pegan SD